Vyriad closed a $25 million final tranche of its Series B financing, taking the round to $85 million and earmarking proceeds to advance VV‑169, its in‑vivo CAR‑T candidate, into first‑in‑human testing for relapsed or refractory multiple myeloma. The company said the funds will support IND enabling work and early clinical operations. The financing underscores investor appetite for in‑vivo cell‑therapy platforms that aim to simplify manufacturing and broaden patient access. Observers will track initial safety readouts and dose‑escalation strategy, which will determine the program’s de‑risking and partnerability.